Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Abstract Purpose: HER2-amplified breast cancer is sometimes clinically insensitive to HER2-targeted treatment with trastuzumab. Laboratory models of resistance have causally implicated changes in HER2 expression and activation of the phosphoinositide 3-kinase (PI3K)–AKT pathway. We conducted a prosp...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sarat Chandarlapaty, Rita A. Sakr, Dilip D. Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford A. Hudis, Tari A. King
Médium: Artigo
Jazyk:angličtina
Vydáno: 2012
On-line přístup:https://doi.org/10.1158/1078-0432.ccr-12-1785
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!